WALTHAM, Mass., Nov. 6, 2025 – Sironax, a global clinical-stage biotechnology company dedicated to discovering and developing transformative therapies for age-related degenerative diseases, today announced the selection of three abstracts for presentation in poster sessions at Neuroscience 2025, the Society for Neuroscience annual meeting in San Diego from November 15 to 19.
Presentation details are below:
Title: Development of a Highly Potent, Brain Penetrant and Allosteric RIPK1 Inhibitor for the Treatment of Neurodegenerative Diseases
Session Name: Alzheimer’s Disease Therapeutic Strategies: Pharmaceutical Approaches
Session Number: PSTR157
Date/Time: November 17, 8 a.m. – 12 p.m. PST
Title: Dose-Dependent and Robust Target Engagement of a Novel Brain Penetrant SARM1 Inhibitor (SIR2501) in Healthy Adult Participants
Session Name: Cellular Stress and Degeneration: Peripheral Degeneration and Neuropathy
Session Number: PSTR271
Date/Time: November 18, 8 a.m. – 12 p.m. PST
Title: Discovery of a Non-covalent, Allosteric SARM1 Inhibitor That Prevents Axonal Degeneration in vitro and in vivo
Session Name: Peripheral Nerve Traumas and Neuropathies
Session Number: PSTR270
Date/Time: November 18, 8 a.m. – 12 p.m. PST
About Sironax
Sironax is a clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic and rare diseases. Founded in 2017, the company has built a diverse pipeline of programs by targeting contributors of aging, degeneration, metabolic dysfunction, and inflammation. Sironax is conducting clinical studies with NAMPT activator SIR4156, SARM1 inhibitor SIR2501, and RIPK1 inhibitor SIR9900, in addition to ongoing preclinical research. The company was named to the 2025 Endpoints 11 list of the most promising biotech startups.